Volume 8 Supplement 1
Abstracts from the 3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis
Meeting abstracts
Edited by Sabine Vogler, Nina Zimmermann and Zaheer-Ud-Din Babar
Publication of this supplement was funded by Gesundheit Osterreich (GOG / Austrian Public Health Institute). The Supplement Editors declare that they have no competing interests.
3rd International PPRI Conference 2015: Pharmaceutical Pricing and Reimbursement Policies: Challenges Beyond the Financial Crisis. Go to conference site.
Vienna, Austria12-13 October 2015
Page 1 of 2
-
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E1
-
Policies beyond the crisis: lesson learned
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E2 -
Policy cooperation and interface issues
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E3 -
The Pharmaceutical Pricing and Reimbursement Information (PPRI) network – a decade of exchange of information and policy research?
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):E4 -
Affordable innovation: future directions in pharmaceutical policy
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K1 -
Managing new premium-priced medicines in Europe
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K2 -
Pharmaceutical pricing and reimbursement policies: perspectives for the future
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K3 -
Priority medicines for Europe and the World: setting a public-health-based medicines development agenda
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K4 -
Pharmaceutical policies in Australia and New Zealand
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K5 -
Scottish collaboration to integrate medicine therapy between out-patient and in-patient sectors
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):K6 -
Financial based agreements and performance based agreements: the Belgian experience
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O1 -
Adapting pharmaceutical reimbursement policies to manage spending on high-priced drugs
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O2 -
Highly innovative drugs in the Czech Republic: retrospective analysis of impact on early market entry, regular reimbursement system entry and public pharmaceutical expenditure
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O3 -
Impact of discounts on medicine prices
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O4 -
A cost/benefit analysis of self-care initiatives in the European Union: who gains, who loses?
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O5 -
Access to subsidised medicines, cost of medicines and health outcomes: exploring general practitioners' perceptions and experiences
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O6 -
Using Multiple Criteria Decision Analysis (MCDA) to make coverage decisions: a methodological framework
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O7 -
Applying Multiple Criteria Decision Analysis (MCDA) in the context of HTA: an experimental case study on metastatic colorectal cancer
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O8 -
Approval, reimbursement and pricing of high-cost cancer medicines in Australia
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O9 -
Introduction of generic substitution and reference pricing in Ireland: early effects on state pharmaceutical expenditure and generic penetration, and associated success factors
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O10 -
Price changes of antibiotics and perceived substitutes in the context of OTC policy changes in Mexico and Brazil
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O11 -
Socioeconomic determinants of medicines use in Central Eastern Europe: the role of pharmaceutical policy in reducing inequalities
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O12 -
Why we should have more collaboration on HTA in Europe: the example of sofosbuvir
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O13 -
The 19th EML as a global standard: an innovative approach or just an opportunity for new and effective medicines?
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O14 -
Collaborative models for increasing efficiency of early drug assessment
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):O15 -
Unintended consequences of co-payment regulations in Belgium: the case of atorvastatin
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P1 -
Impact of Generic Price Linkage System and Reference Price System on prices of pharmaceuticals – comparison of Austria and Finland
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P2 -
Availability and prices of essential medicines for chronic diseases in older people in the Asia Pacific Region
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P3 -
Impact of delisting OTC medicines from reimbursement list
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P4 -
The impact of Ghana's National Health Insurance Scheme median pharmaceutical pricing methodology and reimbursement policy on the pharmaceutical system
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P5 -
Retrospective financial analysis of medicines reimbursement services in community pharmacy
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P6 -
Developing a Drug Price Reference Index in the Philippines
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P7 -
Policy options to deal with high-cost medicines – survey with European policy-makers
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P8 -
A forecasting model for drug utilization and expenditure integrating a Cellular Automata model with the Budget Impact Analysis approach. Preliminary results
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P9 -
Availability and affordability of medicines for children
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P10 -
Determining the prices of the medicines in the absence of superiority over alternative medical technology
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P11 -
Development of pharmaceutical prices in the Republic of Macedonia in comparison to selected countries outside the national reference baskets
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P12 -
30 years of media coverage on high drug prices in the US – a never-ending story or a time for change?
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P13 -
Cost-Containment of Non-Formulary Medicines Accessibility: Malaysian Experience
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P14 -
Value of generic medicines: an health economics study
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P15 -
Prices of oncology medicines in European countries, Australia and New Zealand
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P16 -
Reimbursement policy optimization for Angiotensin-converting enzyme (ACE) inhibitors in Bulgaria: Controlling expenditure without undermining access to treatment
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P17 -
Optimising prescribing in primary care: an evaluation of financial and clinical parameters
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P18 -
Access of high technology medicines in Russia
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P19 -
The prices outpatients have to pay for purchasing medicines in Armenia
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P20 -
Reimbursement measures in European countries – findings of a bibliometric literature review
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P21 -
Insurance-based risk-sharing agreements
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P22 -
Pharmaceutical distribution remuneration in Europe
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P23 -
Reimbursement categories as a way of allocating measures and monitoring expenditures on medicines
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P24 -
The effective and innovative cost saving of software in managing unregistered drugs
Citation: Journal of Pharmaceutical Policy and Practice 2015 8(Suppl 1):P25
- Editorial Board
- Manuscript editing services
- Instructions for Editors
- Sign up for article alerts and news from this journal
-
Official journal of
-
The Journal of Pharmaceutical Policy and Practice is the official journal of the Commonwealth Pharmacists Association.
-
Follow
Annual Journal Metrics
-
2022 Citation Impact
4.2 - 2-year Impact Factor
1.266 - SNIP (Source Normalized Impact per Paper)
0.574 - SJR (SCImago Journal Rank)2022 Speed
9 days submission to first editorial decision for all manuscripts (Median)
97 days submission to accept (Median)2022 Usage
708,141 downloads
5,255 Altmetric mentions